IP Library › Granted Patent US 12,702,746
Granted Patent B2
US 12,702,746 · App. 18/656,245 · Granted Aug 11, 2026

Systems and methods for measuring and tracking wound volume

Inventors: Varuni Rachindra Brownhill (Swanland, GB); Benjamin James Gardner (Hull, GB); Samuel John Mortimer (Kingston upon Hull, GB)
Assignee: T.J.Smith and Nephew, Limited
A61M1/73A61M1/96A61M1/985A61M2205/15A61M2205/3331A61M2205/3584
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,746
App. No.
18/656,245
Filed
May 6, 2024
Granted
Aug 11, 2026
Kind
B2
Art Unit
3781
USPC
604/543
Abstract

A negative pressure wound therapy system can include a negative pressure source configured to provide, via a fluid flow path, negative pressure to a wound covered by a wound dressing. The system can include a controller. The controller can be configured to periodically activate the negative pressure source to maintain negative pressure in the fluid flow path between a low negative pressure setpoint and a high negative pressure setpoint. The controller can be configured to determine a change in a volume of the wound based on a difference between a first time and a second time at which the high negative pressure setpoint has been established in the fluid flow path, the second time being subsequent to the first time. The controller can be configured to provide indication of the change in the volume of the wound.

Claims (46)

1 . A method of operating a negative pressure wound therapy apparatus comprising:

periodically activating a negative pressure source to maintain negative pressure in a fluid flow path connecting the negative pressure source to a wound covered by a wound dressing between a low negative pressure setpoint and a high negative pressure setpoint, the high negative pressure setpoint being associated with higher level of negative pressure than the low negative pressure setpoint;

determining a change in a volume of the wound based on a time duration between a first time at which the high negative pressure setpoint has been established and a second time at which the high negative pressure setpoint has been reestablished in the fluid flow path, the second time being subsequent to the first time; and

providing indication of the change in the volume of the wound,

wherein the method is performed by a controller of the negative pressure wound therapy apparatus.

2 . The method of claim 1 , further comprising:

monitoring the change in the volume of the wound over a duration of time; and

providing indication of progress of healing of the wound based on the change in the volume of the wound monitored over the duration of time.

3 . The method of claim 1 , further comprising determining the change in the volume of the wound based on a difference between the first time and the second time divided by the second time.

4 . The method of claim 1 , further comprising:

determining that negative pressure in the fluid flow path satisfies the high negative pressure setpoint; and

deactivating the negative pressure source responsive to determining that negative pressure in the fluid flow path satisfies the high negative pressure setpoint.

5 . The method of claim 1 , further comprising:

determining that negative pressure in the fluid flow path satisfies the low negative pressure setpoint; and

activating the negative pressure source responsive to determining that negative pressure in the fluid flow path satisfies the low negative pressure setpoint.

6 . The method of claim 1 , wherein determining the change in the volume of the wound is performed without determining a rate of leak in the fluid flow path.

7 . The method of claim 1 , wherein the fluid flow path is configured to not include any openings configured to admit fluid into the fluid flow path at a controlled leak rate.

8 . A method of operating a negative pressure wound therapy apparatus comprising:

determining a volume of a wound based on a first plurality of negative pressure measurements in a fluid flow path connecting a negative pressure source to the wound covered by a wound dressing and a rate of flow of fluid in the fluid flow path, the first plurality of negative pressure measurements being made at a first plurality of times, the first plurality of negative pressure measurements comprising first and second negative pressure measurements made, respectively, at first and second times, the second time being subsequent to the first time, and the second negative pressure measurement corresponding to pressure that is more negative than the first negative pressure measurement; and

providing indication of the volume of the wound,

wherein the method is performed by a controller of the negative pressure wound therapy apparatus.

9 . The method of claim 8 , further comprising, by the controller:

monitoring a change in the volume of the wound over a duration of time; and

providing indication of progress of healing of the wound based on the change in the volume of the wound monitored over the duration of time.

10 . The method of claim 8 , wherein determining the volume of the wound is performed using a product of the rate of flow of fluid in the fluid flow path and a difference between the second and first times divided by a difference between the second and first negative pressure measurements.

11 . The method of claim 10 , wherein the product is scaled by at least one of an ambient temperature or gas constant.

12 . The method of claim 8 , further comprising:

determining a leak rate in the fluid flow path; and

determining the volume of the wound based on the first plurality of negative pressure measurements in the fluid flow path made at the first plurality of times and an adjusted rate of flow of fluid in the fluid flow path, the adjusted rate of flow of fluid in the fluid flow path being determined based on subtracting the leak rate from the rate of flow of fluid in the fluid flow path.

13 . The method of claim 12 , further comprising:

determining the leak rate in the fluid flow path based on the volume of the wound and a second plurality of negative pressure measurements in the fluid flow path made at a second plurality of times, the second plurality of negative pressure measurements including third and fourth negative pressure measurements made, respectively, at third and fourth times, the fourth time being subsequent to the third time, and the fourth negative pressure measurement corresponding to pressure that is more positive than the third negative pressure measurement.

14 . The method of claim 13 , wherein determining the leak rate is performed using a product of the volume of the wound and a difference between the fourth and third negative pressure measurements divided by a difference between the fourth and third times.

15 . The method of claim 14 , wherein the difference between the fourth and third times is scaled by at least one of an ambient temperature or gas constant.

16 . The method of claim 8 , wherein determining the volume of the wound is performed without determining a rate of leak in the fluid flow path.

17 . The method of claim 8 , further comprising:

determining a first leak rate in the fluid flow path based on the volume of the wound;

determining a second leak rate in the fluid flow path using a flow meter or based on a level of activity of the negative pressure source; and

verifying that the volume of the wound has been accurately determined based on a determination that the first leak rate matches the second leak rate.

18 . The method of claim 8 , further comprising, by the controller:

determining a leak rate in the fluid flow path based on the volume of the wound; and

verifying that the volume of wound has been accurately determined based on a determination that first leak rate matches a known leak rate in the fluid flow path.

19 . The method of claim 8 , further comprising, by the controller:

periodically activating the negative pressure source to maintain negative pressure in the fluid flow path between a low negative pressure setpoint and a high negative pressure setpoint, the high negative pressure setpoint being associated with higher level of negative pressure than the low negative pressure setpoint.

20 . The method of claim 19 , wherein periodically activating the negative pressure source to maintain negative pressure in the fluid flow path between the low negative pressure setpoint and the high negative pressure setpoint comprises:

at a first time, determining that negative pressure in the fluid flow path satisfies the low negative pressure setpoint and activating the negative pressure source responsive to determining that negative pressure in the fluid flow path satisfies the low negative pressure setpoint; and

at a second time, determining that negative pressure in the fluid flow path satisfies the high negative pressure setpoint and deactivating the negative pressure source in response to determining that negative pressure in the fluid flow path measured satisfies the high negative pressure setpoint.

Priority Claims (1)
GB 2001212 · Jan 29, 2020 · national
Continuity (2)
Continuation 17759502 · Jan 21, 2021
Related Publication 20240285845A1 · Aug 29, 2024
References Cited (241)
US 2923298A · Dockstader et al. · 1960 [cited by applicant]
US 3972328A · Chen · 1976 [cited by applicant]
US 4029598A · Neisius et al. · 1977 [cited by applicant]
US 4728499A · Fehder · 1988 [cited by applicant]
US 4813942A · Alvarez · 1989 [cited by applicant]
US 5056510A · Gilman · 1991 [cited by applicant]
US 5181905A · Flam · 1993 [cited by applicant]
US 5238732A · Krishnan · 1993 [cited by applicant]
US 5549584A · Gross · 1996 [cited by applicant]
US 5707499A · Joshi et al. · 1998 [cited by applicant]
US 5759570A · Arnold · 1998 [cited by applicant]
US 5852126A · Barnard et al. · 1998 [cited by applicant]
US 6071267A · Zamierowski · 2000 [cited by applicant]
US 6626891B2 · Ohmstede · 2003 [cited by applicant]
US 6685681B2 · Lockwood et al. · 2004 [cited by applicant]
US 6752794B2 · Lockwood et al. · 2004 [cited by applicant]
US 6936037B2 · Bubb et al. · 2005 [cited by applicant]
US 6951553B2 · Bubb et al. · 2005 [cited by applicant]
US 6979324B2 · Bybordi et al. · 2005 [cited by applicant]
US 7070584B2 · Johnson et al. · 2006 [cited by applicant]
US 7108683B2 · Zamierowski · 2006 [cited by applicant]
US 7216651B2 · Argenta et al. · 2007 [cited by applicant]
US 7361184B2 · Joshi · 2008 [cited by applicant]
US 7381859B2 · Hunt et al. · 2008 [cited by applicant]
US 7605298B2 · Bechert et al. · 2009 [cited by applicant]
US 7615036B2 · Joshi et al. · 2009 [cited by applicant]
US 7622629B2 · Aali · 2009 [cited by applicant]
US 7625362B2 · Boehringer et al. · 2009 [cited by applicant]
US 7700819B2 · Ambrosio et al. · 2010 [cited by applicant]
US 7718249B2 · Russell et al. · 2010 [cited by applicant]
US 7722582B2 · Lina et al. · 2010 [cited by applicant]
US 7749531B2 · Booher · 2010 [cited by applicant]
US 7759537B2 · Bishop et al. · 2010 [cited by applicant]
US 7759539B2 · Shaw et al. · 2010 [cited by applicant]
US 7775998B2 · Riesinger · 2010 [cited by applicant]
US 7811269B2 · Boynton et al. · 2010 [cited by applicant]
US 7910791B2 · Coffey · 2011 [cited by applicant]
US 7922703B2 · Riesinger · 2011 [cited by applicant]
US 7959624B2 · Riesinger · 2011 [cited by applicant]
US 7976519B2 · Bubb et al. · 2011 [cited by applicant]
US 8062331B2 · Zamierowski · 2011 [cited by applicant]
US 8152785B2 · Vitaris · 2012 [cited by applicant]
US 8162907B2 · Heagle · 2012 [cited by applicant]
US 8235972B2 · Adahan · 2012 [cited by applicant]
US 8241261B2 · Randolph et al. · 2012 [cited by applicant]
US 8372049B2 · Jaeb et al. · 2013 [cited by applicant]
US 8372050B2 · Jaeb et al. · 2013 [cited by applicant]
US 8425478B2 · Olson · 2013 [cited by applicant]
US 8513481B2 · Gergely et al. · 2013 [cited by applicant]
US 8540688B2 · Eckstein et al. · 2013 [cited by applicant]
US 8545466B2 · Andresen et al. · 2013 [cited by applicant]
US 8568386B2 · Malhi · 2013 [cited by applicant]
US 8628505B2 · Weston · 2014 [cited by applicant]
US 8641691B2 · Fink et al. · 2014 [cited by applicant]
US 8663198B2 · Buan et al. · 2014 [cited by applicant]
US 8795243B2 · Weston · 2014 [cited by applicant]
US 8795800B2 · Evans · 2014 [cited by applicant]
US 8814841B2 · Hartwell · 2014 [cited by applicant]
US 8905985B2 · Allen et al. · 2014 [cited by applicant]
US 9012714B2 · Fleischmann · 2015 [cited by applicant]
US 9067003B2 · Buan et al. · 2015 [cited by applicant]
US 9127665B2 · Locke et al. · 2015 [cited by applicant]
US 9220822B2 · Hartwell · 2015 [cited by applicant]
US 9283118B2 · Locke et al. · 2016 [cited by applicant]
US 9302033B2 · Riesinger · 2016 [cited by applicant]
US 9375521B2 · Hudspeth et al. · 2016 [cited by applicant]
US 9381283B2 · Adams et al. · 2016 [cited by applicant]
US 9421309B2 · Robinson et al. · 2016 [cited by applicant]
US 9427505B2 · Askem et al. · 2016 [cited by applicant]
US 9452248B2 · Blott et al. · 2016 [cited by applicant]
US 9629986B2 · Patel et al. · 2017 [cited by applicant]
US 9681993B2 · Wu et al. · 2017 [cited by applicant]
US 9682179B2 · May · 2017 [cited by applicant]
US 9795725B2 · Joshi et al. · 2017 [cited by applicant]
US 9808561B2 · Adie et al. · 2017 [cited by applicant]
US 9829471B2 · Hammond et al. · 2017 [cited by applicant]
US 9844473B2 · Blott et al. · 2017 [cited by applicant]
US 9962474B2 · Greener · 2018 [cited by applicant]
US 10016309B2 · Hartwell · 2018 [cited by applicant]
US 10046096B2 · Askem et al. · 2018 [cited by applicant]
US 10105471B2 · Weston · 2018 [cited by applicant]
US 10188555B2 · Vitaris et al. · 2019 [cited by applicant]
US 10201644B2 · Haggstrom et al. · 2019 [cited by applicant]
US 10328188B2 · Deutsch et al. · 2019 [cited by applicant]
US 10493184B2 · Collinson et al. · 2019 [cited by applicant]
US 10881324B2 · Ryu et al. · 2021 [cited by applicant]
US 11253401B2 · Pratt et al. · 2022 [cited by applicant]
US 11364334B2 · Long et al. · 2022 [cited by applicant]
US 20020087136A1 · Widlund · 2002 [cited by applicant]
US 20030125646A1 · Whitlock · 2003 [cited by applicant]
US 20040057855A1 · Gerlach et al. · 2004 [cited by applicant]
US 20050222544A1 · Weston · 2005 [cited by applicant]
US 20060009744A1 · Erdman et al. · 2006 [cited by applicant]
US 20070040454A1 · Freudenberger et al. · 2007 [cited by applicant]
US 20070225663A1 · Watt et al. · 2007 [cited by applicant]
US 20070255194A1 · Gudnason et al. · 2007 [cited by applicant]
US 20080031748A1 · Ihle et al. · 2008 [cited by applicant]
US 20080132821A1 · Propp et al. · 2008 [cited by applicant]
US 20080223378A1 · Henderson et al. · 2008 [cited by applicant]
US 20090125004A1 · Shen et al. · 2009 [cited by applicant]
US 20090157024A1 · Song · 2009 [cited by applicant]
US 20090234306A1 · Vitaris · 2009 [cited by applicant]
US 20090299306A1 · Buan · 2009 [cited by applicant]
US 20100125258A1 · Coulthard et al. · 2010 [cited by applicant]
US 20100259406A1 · Caso et al. · 2010 [cited by applicant]
US 20100318052A1 · Ha et al. · 2010 [cited by applicant]
US 20110004172A1 · Eckstein et al. · 2011 [cited by applicant]
US 20110224631A1 · Simmons et al. · 2011 [cited by applicant]
US 20120051945A1 · Orndorff et al. · 2012 [cited by applicant]
US 20130066285A1 · Locke et al. · 2013 [cited by applicant]
US 20130066289A1 · Song et al. · 2013 [cited by applicant]
US 20130090616A1 · Neubauer · 2013 [cited by applicant]
US 20130138054A1 · Fleischmann · 2013 [cited by applicant]
US 20130144227A1 · Locke et al. · 2013 [cited by applicant]
US 20130150813A1 · Gordon · 2013 [cited by examiner]
US 20130165878A1 · Heagle · 2013 [cited by applicant]
US 20130296762A1 · Toth · 2013 [cited by applicant]
US 20130302545A1 · Schnelker et al. · 2013 [cited by applicant]
US 20140114268A1 · Auguste et al. · 2014 [cited by applicant]
US 20140200533A1 · Whyte et al. · 2014 [cited by applicant]
US 20140316359A1 · Collinson et al. · 2014 [cited by applicant]
US 20150032035A1 · Banwell et al. · 2015 [cited by applicant]
US 20150119831A1 · Robinson et al. · 2015 [cited by applicant]
US 20150119832A1 · Locke · 2015 [cited by applicant]
US 20150119833A1 · Coulthard et al. · 2015 [cited by applicant]
US 20160000611A1 · Niederauer et al. · 2016 [cited by applicant]
US 20160101278A1 · Norris · 2016 [cited by examiner]
US 20160298620A1 · Cordoba et al. · 2016 [cited by applicant]
US 20170128642A1 · Buan · 2017 [cited by applicant]
US 20170368239A1 · Askem · 2017 [cited by examiner]
US 20180104391A1 · Luxon · 2018 [cited by examiner]
US 20180133378A1 · Askem et al. · 2018 [cited by applicant]
US 20180318476A1 · Askem et al. · 2018 [cited by applicant]
US 20190192744A1 · Greener et al. · 2019 [cited by applicant]
US 20190298579A1 · Moore · 2019 [cited by examiner]
US 20200061253A1 · Long · 2020 [cited by examiner]
US 20200121833A9 · Askem et al. · 2020 [cited by applicant]
US 20200139023A1 · Haggstrom et al. · 2020 [cited by applicant]
US 20200246194A1 · Gonzalez et al. · 2020 [cited by applicant]
US 20200306422A1 · Moore et al. · 2020 [cited by applicant]
US 20210085838A1 · Locke · 2021 [cited by examiner]
DE 3443101A1 · 1986 [cited by applicant]
DE 19535537A1 · 1997 [cited by applicant]
DE 19700271A1 · 1997 [cited by applicant]
DE 202004017052U1 · 2005 [cited by applicant]
EP 0091800A1 · 1983 [cited by applicant]
EP 0122042A2 · 1984 [cited by applicant]
EP 0340018A2 · 1989 [cited by applicant]
EP 0999858B1 · 2004 [cited by applicant]
EP 1476217B1 · 2008 [cited by applicant]
EP 1955887A2 · 2008 [cited by applicant]
EP 2140968A2 · 2010 [cited by applicant]
EP 2462908A1 · 2012 [cited by applicant]
EP 3257438A1 · 2017 [cited by examiner]
EP 2821035B1 · 2019 [cited by applicant]
EP 3269404B1 · 2020 [cited by applicant]
EP 4096735A1 · 2022 [cited by applicant]
FR 1163907A · 1958 [cited by applicant]
GB 1255395A · 1971 [cited by applicant]
GB 2093190A · 1982 [cited by applicant]
GB 2307180B · 2000 [cited by applicant]
GB 2468905A · 2010 [cited by applicant]
WO WO8300742A1 · 1983 [cited by applicant]
WO WO9216245A1 · 1992 [cited by applicant]
WO WO9605873A1 · 1996 [cited by applicant]
WO WO0134223A1 · 2001 [cited by applicant]
WO WO03045492A1 · 2003 [cited by applicant]
WO WO2004060148A2 · 2004 [cited by applicant]
WO WO2004077387A1 · 2004 [cited by applicant]
WO WO2005046760A1 · 2005 [cited by applicant]
WO WO2005105180A1 · 2005 [cited by applicant]
WO WO2006052338A2 · 2006 [cited by applicant]
WO WO2007015964A1 · 2007 [cited by applicant]
WO WO2007059742A1 · 2007 [cited by applicant]
WO WO2007085396A1 · 2007 [cited by applicant]
WO WO2007113597A2 · 2007 [cited by applicant]
WO WO2007118652A1 · 2007 [cited by applicant]
WO WO2008039223A1 · 2008 [cited by applicant]
WO WO2009019227A2 · 2009 [cited by applicant]
WO WO2009060097A2 · 2009 [cited by applicant]
WO WO2009124100A1 · 2009 [cited by applicant]
WO WO2009145703A1 · 2009 [cited by applicant]
WO WO2009147402A2 · 2009 [cited by applicant]
WO WO2009158128A2 · 2009 [cited by applicant]
WO WO2010142959A2 · 2010 [cited by applicant]
WO WO2011135285A1 · 2011 [cited by applicant]
WO WO2011135286A1 · 2011 [cited by applicant]
WO WO2011135287A1 · 2011 [cited by applicant]
WO WO2011144888A1 · 2011 [cited by applicant]
WO WO2012131237A1 · 2012 [cited by applicant]
WO WO2012143665A1 · 2012 [cited by applicant]
WO WO2013010907A1 · 2013 [cited by applicant]
WO WO2013064852A1 · 2013 [cited by applicant]
WO WO2013083800A1 · 2013 [cited by applicant]
WO WO2013090810A1 · 2013 [cited by applicant]
WO WO2013149078A1 · 2013 [cited by applicant]
WO WO2014008348A2 · 2014 [cited by applicant]
WO WO2014016759A1 · 2014 [cited by applicant]
WO WO2014020440A1 · 2014 [cited by applicant]
WO WO2014020443A2 · 2014 [cited by applicant]
WO WO2014108476A1 · 2014 [cited by applicant]
WO WO2015022334A1 · 2015 [cited by applicant]
WO WO2015022340A1 · 2015 [cited by applicant]
WO WO2016018448A1 · 2016 [cited by applicant]
WO WO2016174048A1 · 2016 [cited by applicant]
WO WO2018096390A1 · 2018 [cited by applicant]
WO WO2018164803A1 · 2018 [cited by applicant]
WO WO2019023311A1 · 2019 [cited by applicant]
Advantec MFS, Inc., “Membrane Filters” (catalog), retrieved from http://www.advantecmfs.com/catalog/filt/membrane.pdf, on Jan. 29, 2016, Copyright 2001-2011, 17 pages. [cited by applicant]
Hersle K., et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies,” The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, pp. 35-37. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2021/051264, mailed on Aug. 11, 2022, 9 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2021/051264, mailed on Mar. 29, 2021, 15 pages. [cited by applicant]
Kendall Ultec Hydrocolloid Dressing (4″x4″), Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page. [cited by applicant]
Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation). [cited by applicant]
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System,” Spiral Booklet, Mar. 2011, 7 pages. [cited by applicant]
Technology Watch, May 1989, 1 page. [cited by applicant]
Affidavit of Dr. Viktoria Skeppstedt filed in the Opposition against European Patent No. 4223265, dated May 19, 2025, 2 pages. [cited by applicant]
Allevyn Adhesive., “SMTL Dressings Datacard,” Smith and Nephew Healthcare Ltd, last modified May 11, 2007, 3 pages. [cited by applicant]
Anonymous, “3M Tegaderm Transparent Film Dressings—Product Profile,” Retrieved from http://multimedia.3m.com/mws/media/447983O/tegaderm-transparent-film-dressing-brochure.pdf, Jan. 1, 2012, 8 pages. [cited by applicant]
Bartels V.T., “Handbook of Medical Textiles,” © Woodhead Publishing Limited, 2011, 115 pages. [cited by applicant]
Declaration of Chris Locke Submitted in the Opposition against European Patent No. 2231221, mailed on Sep. 7, 2016, 1 page. [cited by applicant]
Definition of “Strand,” Collins English Dictionary, accessed Apr. 11, 2024, 15 pages, URL: https://www.collinsdictionary.com/dictionary/english/strand. [cited by applicant]
Definition of “System,” Cambridge Dictionary, accessed Apr. 11, 2024, 8 pages, URL:https://dictionary.cambridge.org/dictionary/english/system. [cited by applicant]
Du Pont, “Material Safety Data Sheet—Dupont Spunlaced Nonwoven Fabric Version 2.0”, revision date May 5, 2009, filed in the Opposition against European Patent No. 3628289 on Aug. 8, 2025, 5 pages. [cited by applicant]
“Search Results from UK Intellectual Property Office Trade Mark Register,” filed in the Opposition for the European Patent No. 4023197 on Dec. 15, 2023, 3 pages. [cited by applicant]
EN 13726-2:2002. “Test methods for primary wound dressings—Part 2: Moisture vapour transmission rate of permeable film dressings,” Brussels: European Committee for Standardization (CEN), 2002., 11 pages. [cited by applicant]
“Handbook of Medical Textiles,” Woodhead Publishing Limited, 2011, 41 pages. [cited by applicant]
Hutten I.M., “Introduction to Nonwoven Filter Media”, in Handbook of Nonwoven Filter Media, 2007, 1 page. [cited by applicant]
Merriam-Webster, Definition of “Port”, Retrieved from the Internet: https://www.merriam-webster.com/dictionary/port?src=search-diet-box, Accessed on Feb. 7, 2025, 1 page. [cited by applicant]
Merriam-Webster, Definition of Port, retrieved from URL: https://www.merriam-webster.com/dictionary/port, on Oct. 26, 2020, 6 pages. [cited by applicant]
Phan T T., et al., “Evaluation of cell culture on the polyurethane-based membrane (Tegaderm): implication for tissue engineering of skin,” Cell Tissue Bank. 2005; 6(2), 1 page. [cited by applicant]
Riedel E., et al., “Verbandstoff-Fibel,” 5. Auflage, Stuttgart, 1995, Seiten 23-35 and 82-95. [cited by applicant]
Russell S.J., et al., “18—Anisotropic Fluid Transmission in Nonwoven Wound Dressings,” Proceedings of the 2nd International Conference, Aug. 24 & 25, 1999, Woodhead Publishing Series in Textiles, 2001, 1 page. [cited by applicant]
Saul D Harrison & Sons PLC, “DuPont Sontara—Wiping solutions” [brochure], filed in the Opposition against European Patent No. 3628289 on Aug. 8, 2025, 4 pages. [cited by applicant]
Silverlon, “Negative Pressure Contact Dressings,” retrieved from Internet URL: https://www.silverlon.com/products/negative-pressure-contact-dressings , accessed on Jan. 24, 2022, 10 pages. [cited by applicant]
“Technical datasheet for the Chem-PositeTM 11C-450 material,” Emerging Technologies, filed in the Opposition for the European Patent No. 4023197 on Apr. 29, 2024 (publication date unknown), 1 page. [cited by applicant]
“The Allevyn Wound Dressings Range” 1 page, Product brochure obtained from: https://www.smith-nephew.com/en-pb/health-care-professionals/products/advanced-wound-management/allevynborder-gilobal-new#relatedtechnologies. [cited by applicant]
The Wayback Machine, “Cellulose fiber,” Extract from Wikipedia, the free encyclopedia, Retrieved from the Internet: URL: http://en.wikipedia.org/wiki/Cellulose_fiber, Online, on 2009, 1 page. [cited by applicant]
The Wayback Machine, “Rayon Fiber,” Extract from Conservation and Art Material Encyclopaedia Online, on Mar. 13, 2006, 1 page. [cited by applicant]
“Strand,” Wiktionary, last edited Mar. 25, 2024 (accessed Apr. 11, 2024), 10 pages, URL: https://en.wiktionary.org/wiki/strand. [cited by applicant]
Wikipedia, Definition of “Rayon” being Regenerated Cellulose, Retrieved from the Internet: https://en.wikipedia.org/wiki/Rayon, on Feb. 7, 2025, 1 page. [cited by applicant]